PK workshop: new drugs and drug interactions

Introduction

This important annual workshop always includes studies that are not presented to other meetings.

Studies in this issue of HTB include:

• Studies on pipeline ARVs: Quad, evitegravir/cobicistat, cobisistat, GSK1265744, BMS986001 dolutegravir, GSK-1265744, long acting formulations (monthly injections): rilpivirine-LA, raltegravir and patient views

• Interactions between malaria drugs and etravirine or darunavir/r

• No interaction between antimalarial amodiaquine and nevirapine

• Atazanavir/ritonavir and voriconazole not to be coadministered

• Pharmacokinetics of atazanavir/ritonavir plus raltegravir

• Echinacea and etravirine

• Warfarin and ARVs: impact of African American race and ritonavir

Reports on drug interactions are selected, and in some cases summarised, from a full report produced by the pharmacology group at Liverpool University (www.druginteractions.org).

The full Liverpool report is available online and in PDF format.

http://www.hiv-druginteractions.org/data/NewsItem/94_13%20PKW%20Barcelona.pdf (PDF)

It is appreciated that the organisers enable both the programme and abstract book to be available download in PDF format.

http://www.virology-education.com/

http://regist2.virology-education.com/abstractbook/2012_3.pdf

Abbreviations used in these reports:

Cmax = Maximum concentration; Cmin = minimum concentration; AUC = Area Under the Curve; GMR = Geometric Mean Ratio; IC90/50 = Inhibitory Concentration needed to reduce viral production by 90/50% in vitro.